Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
出版年份 2020 全文链接
标题
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
作者
关键词
-
出版物
Blood Advances
Volume 4, Issue 9, Pages 2032-2043
出版商
American Society of Hematology
发表日期
2020-05-12
DOI
10.1182/bloodadvances.2019000757
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
- (2019) Daniel A. Pollyea et al. CURRENT OPINION IN HEMATOLOGY
- Venetoclax-based Therapies for Acute Myeloid Leukemia
- (2019) Veronica A. Guerra et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- FDA Approval Summary: Glasdegib for newly-diagnosed acute myeloid leukemia
- (2019) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- Unfolded Protein Response (UPR) in Survival, Dormancy, Immunosuppression, Metastasis, and Treatments of Cancer Cells
- (2019) Sheng-Kai Hsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Glasdegib with Low-Dose Cytarabine - A New Upfront Option for the Vulnerable AML Patient
- (2019) Amir T Fathi CLINICAL CANCER RESEARCH
- The molecular mechanisms of chemoresistance in cancers
- (2017) Hua-Chuan Zheng Oncotarget
- Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
- (2016) Hsiao-Hui Lin et al. CANCER LETTERS
- Wnt signaling and cellular metabolism in osteoblasts
- (2016) Courtney M. Karner et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Drugging the unfolded protein response in acute leukemias
- (2015) Behzad Kharabi Masouleh et al. Journal of Hematology & Oncology
- Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia
- (2014) Smita Dandekar et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
- (2014) W Fiskus et al. LEUKEMIA
- Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target
- (2013) Yang Yang et al. CANCER LETTERS
- Wnt Signaling in Normal and Malignant Hematopoiesis
- (2013) W. Lento et al. Cold Spring Harbor Perspectives in Biology
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2011) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
- (2010) Y. Wang et al. SCIENCE
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- Evidence that Fold-Change, and Not Absolute Level, of β-Catenin Dictates Wnt Signaling
- (2009) Lea Goentoro et al. MOLECULAR CELL
- Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
- (2008) Jinglan Xu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells
- (2008) Katharina Salome Minke et al. EUROPEAN JOURNAL OF HAEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started